371 related articles for article (PubMed ID: 11103751)
1. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Varis T; Kivistö KT; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
[TBL] [Abstract][Full Text] [Related]
2. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
Varis T; Backman JT; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Mar; 67(3):215-21. PubMed ID: 10741623
[TBL] [Abstract][Full Text] [Related]
3. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
4. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.
Neuvonen PJ; Jalava KM
Clin Pharmacol Ther; 1996 Jul; 60(1):54-61. PubMed ID: 8689812
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol.
Lilja JJ; Backman JT; Laitila J; Luurila H; Neuvonen PJ
Clin Pharmacol Ther; 2003 Mar; 73(3):192-8. PubMed ID: 12621384
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole greatly increases plasma concentrations and effects of felodipine.
Jalava KM; Olkkola KT; Neuvonen PJ
Clin Pharmacol Ther; 1997 Apr; 61(4):410-5. PubMed ID: 9129558
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.
Varis T; Kaukonen KM; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Oct; 64(4):363-8. PubMed ID: 9797792
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
9. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.
Yasui-Furukori N; Saito M; Niioka T; Inoue Y; Sato Y; Kaneko S
Ther Drug Monit; 2007 Feb; 29(1):45-8. PubMed ID: 17304149
[TBL] [Abstract][Full Text] [Related]
10. The effect of ingestion time interval on the interaction between itraconazole and triazolam.
Neuvonen PJ; Varhe A; Olkkola KT
Clin Pharmacol Ther; 1996 Sep; 60(3):326-31. PubMed ID: 8841155
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
12. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
Villikka K; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
[TBL] [Abstract][Full Text] [Related]
13. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
14. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers.
Varis T; Kivistö KT; Backman JT; Neuvonen PJ
Pharmacol Toxicol; 1999 Jul; 85(1):29-32. PubMed ID: 10426160
[TBL] [Abstract][Full Text] [Related]
15. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
[TBL] [Abstract][Full Text] [Related]
17. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
McCrea JB; Majumdar AK; Goldberg MR; Iwamoto M; Gargano C; Panebianco DL; Hesney M; Lines CR; Petty KJ; Deutsch PJ; Murphy MG; Gottesdiener KM; Goldwater DR; Blum RA
Clin Pharmacol Ther; 2003 Jul; 74(1):17-24. PubMed ID: 12844131
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.
Raaska K; Niemi M; Neuvonen M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Oct; 72(4):362-9. PubMed ID: 12386638
[TBL] [Abstract][Full Text] [Related]
20. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans.
Herman BD; Fleishaker JC; Brown MT
Clin Pharmacol Ther; 1999 Oct; 66(4):374-9. PubMed ID: 10546921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
